Clinical Trials - April 13, 2026
Diamyd Medical discontinues Phase 3 trial and initiates strategic review
Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.
Acquisition - April 13, 2026
Getinge acquires Pennamed
Getinge has acquired Pennamed, a UK-based distributor of endoscopic consumables serving National Health Service (NHS) and independent healthcare providers.
In a new job - April 10, 2026
Malin Grape becomes Special Advisor to WHO
Grape is to be appointed Special Advisor on antimicrobial resistance (AMR) to the WHO European Region.
In a new job - April 10, 2026
Pharmability appoints Consulting Clinical Project Manager
The appointment of Agneta Wennerholm supports the company's preparations for the clinical development of TIR-C, a novel immunomodulatory drug candidate for the treatment of atopic dermatitis (eczema).
Science News - April 9, 2026
Immune cells in the nose slow influenza virus
A new study from the University of Gothenburg may help guide the development of better influenza vaccines.
Business article - April 7, 2026
Zealand Pharma establishes US Research Hub in Cambridge
The new research hub in Cambridge, Massachusetts, in the greater Boston area, will serve as Zealand Pharma’s primary US address and is expected to be operational from September 2026.
